Piperine and bioavailability: how the absorption of certain substances in the body changes

Bioavailability is the proportion of a substance that, after intake, reaches the blood in a usable form. It describes not only intestinal absorption, but also what happens before and after this process. The compound may degrade in the intestine, cross the epithelium (the layer of cells in the wall), and undergo further modifications. For this reason, two molecules taken at the same dose can produce different outcomes.

Piperine is of interest as a potential bioenhancer (a substance that increases the available amount) of another compound. It does not ensure total absorption, but it can act on certain steps that limit the quantity used by the body. Dietary guidelines and public documents include spices in a healthy eating pattern. However, their use to alter the pathway of other substances in the body requires a separate evaluation [1][2]. Reviews indicate that studies focus on absorption, modifications in the body, and toxicity, rather than a guaranteed increase in efficacy [3][4]. On this basis, it is necessary to understand the role played by the intestine.

The most extensive reviews study this molecule in relation to absorption, changes in the body, and formulation. However, the response changes depending on the compound it is paired with. Its action as a bioenhancer therefore appears selective and does not apply equally to every substance. This data explains why there are numerous hypotheses regarding the mechanisms, but fewer direct clinical trials.

The clearest point remains the meaning of bioavailability: it is a concrete biological measure, not a marketing slogan. A 2021 review summarized studies on chemical properties, absorption, metabolism, bioavailability, and toxicity. Another publication from the same year also examined new delivery systems and differences in the absorbed amount [5][6]. A 2026 review noted bioenhancing activity. However, poor water solubility, varying individual responses, and the limitations of clinical trials hinder general use [7]. The current picture helps to understand the topic, but does not yet allow for definitive conclusions.

Membrane transporters are proteins that regulate the passage of molecules through intestinal cells. They are located on the wall of the cells lining the intestine. Some facilitate the entry of substances into the bloodstream. Others limit their accumulation by pushing them back toward the intestinal lumen. This second mechanism is called efflux. It reduces the amount of substance that remains inside the cell. In this context, piperine has been studied as a potential modulator of these systems. The underlying idea is simple: if it can curb efflux, the substance remains in the intestinal cell for longer. This can promote the intracellular retention of certain substances. This increases the likelihood that they will reach the bloodstream. This does not mean it happens every time, nor with every molecule.

A 2025 review describes piperine as a natural bioenhancer capable of inhibiting cytochrome P450 enzymes, particularly CYP3A4, and efflux transporters such as P-gp [8]. This data is useful for explaining the mechanism, but it is not enough to predict the actual effect in every person or with every formulation. The next hurdle is first-pass metabolism, which can further reduce the available amount.

First-pass metabolism transforms a substance in the intestine and liver before it enters the bloodstream. If this phase is rapid, a smaller amount may reach the tissues. This reduces systemic exposure (the quantity present in the blood and available to the body). Piperine is studied because, in some models, it appears to act on this phase for specific compounds: it does not seem to block all metabolism indiscriminately.

In a study on rats, pretreatment caused some changes within 6 hours. In the liver, the expression (gene activity) of UGT1A6, UGT1A8, SULT1A1, and SULT1A3 changed. In the colon, that of UGT1A6 varied. Values returned toward initial levels at 8 hours. The variations occurred alongside changes in exposure to curcumin [9]. The result indicates a possible mechanism, but it comes from animals and shows a temporary effect: it is therefore not a rule applicable to every substance, product, or person.

This pair is a study model because it brings together two substances with different roles. One enters the bloodstream poorly, while the other can change its pathway in the body. After consumption, curcumin is poorly absorbed and rapidly metabolized. For this reason, researchers are evaluating whether a different formula can increase its bioavailability (the portion that reaches the blood).

A study on rats and 12 human volunteers compared two preparations. The first contained 2 g of curcumin alone; the second added piperine at 20 mg/kg. Biological availability increased by 154% in rats and 2000% in humans. The time to reach the peak also increased, while elimination decreased [10]. The data is strong, but the human group was small and the test followed a very specific plan. The result, therefore, applies to this specific case and not to all products containing these compounds.

In clinical trials, researchers have also studied the visible effects on people. A trial is a study that evaluates an intervention in a group of volunteers or patients. In a randomized study on patients with COVID-19, the product provided 525 mg of curcumin and 2.5 mg of piperine twice a day. The pair was therefore tested in a clinical setting, not just in pharmacokinetic studies [11].

A meta-analysis that combined 20 randomized trials brought together groups ranging from 8 to 117 people. The studies lasted from 1 to 12 weeks and used doses between 5 and 15 mg per day and between 500 and 1500 mg per day. In 15 out of 20 cases, CRP, hs-CRP, and IL-6 (indices related to inflammation) decreased [12]. However, the groups, objectives, and products were different. The signal is therefore useful, but it does not apply uniformly. The pair appears promising, without becoming a rule valid for every use.

The most recent evidence is useful because it prevents describing piperine as an always-effective enhancer. In an independent crossover study on 9 healthy men, using 3 formulations of approximately 570 mg and tests up to 2280 mg with and without piperine, the addition of the molecule did not lead to an appreciable advantage and plasma levels of unconjugated curcumin remained very low [13]. This data shows that the enhancing effect is not automatic. The body's response depends on many factors, such as the dose and the form of the product.

Another in vitro study compared the curcumin-piperine combination with turmeric rhizomes to show how the delivery vehicle can change the formulation and therefore the final response [14]. In practice, the result depends on the context: simply adding piperine is not enough to automatically obtain greater bioavailability. These data do not refute positive studies, but they serve as a reminder that bioenhancement is possible only under certain conditions and should not be extended without caution to other ingredients or to all preparations.

The response to piperine depends not only on its presence but also on how a substance is absorbed and processed. Some compounds may benefit from the modulation of membrane transporters or reduced passage through metabolic enzymes. Others follow different pathways and remain almost unchanged. Piperine can inhibit enzymes such as CYP3A4 and P-glycoprotein, which act as gates in the intestine and liver. When these gates close, more of the molecule enters the bloodstream.

However, if a substance does not use those gates, the effect of piperine is negligible. This is why the concept of a bioenhancer is useful, but not uniform: the same strategy may help one molecule while leaving another unaffected. In other words, the mechanism exists, but its application depends on the substance, the dose, and the formulation. The point is not whether piperine “works,” but for which compounds, under what conditions, and with what predictability.

Formulation is the way in which an ingredient is made absorbable: capsules, tablets, extracts, and delivery systems can change the amount that actually reaches the body. This is decisive for piperine, because the same molecule can yield different results if the vehicle changes. A capsule that dissolves slowly releases its contents gradually. A poorly compressed tablet may not disintegrate completely. Particle size and the presence of excipients also matter.

When the main issue is incomplete release or poor solubility, increasing the dose is not enough to achieve better bioavailability. The message is clear: the product's behavior cannot be deduced from the label, but from the way the mixture is constructed and tested. The limitation is that the results of one formulation cannot be automatically transferred to all others, even when the active ingredient is the same.

Piperine is interesting precisely because it interacts with other compounds, making it a good model of nutraceutical synergy. However, this same characteristic also complicates its practical use: a combination can modify systemic exposure in a favorable way, or it can make the result less predictable. When two substances act together, the effect of one may be amplified, but it can also generate variability between individuals. Factors such as the gut microbiota and transit speed can play a role.

For this reason, "enhancing" does not automatically mean improving, especially when moving from the laboratory to daily supplementation. In rats and 12 human volunteers, 2 g of curcumin with 20 mg/kg of piperine increased systemic exposure by 154% in rats and 2000% in humans, with an increase in the time required to reach peak blood levels and a longer residence time of the substance in the body. The limitation is precisely this: a strong result for one combination does not authorize extending it to all compounds or all products.